Brought to you by 
Series B brings in $6.4mm for Avaxia; adds $5mm
07 Jun 2013
Executive Summary
Avaxia Biologics Inc. (developing therapeutics for gastrointestinal and metabolic diseases) has raised $6.4mm via its Series B financing led by returning backer Cherrystone Angels and new investor Golden Seeds. Other existing shareholders Beacon Angels, Boston Harbor Angels, Launchpad Venture Group, Mass Medical Angels, and North Country Angels were joined by first-time backers the Beta Fund, Granite State Angels, the Keiretsu Forum, and Maine Angels, plus individual investors. Avaxia will use the proceeds for a Phase Ib trial of its oral anti-TNF antibody AVX470 for ulcerative colitis. Patient enrollment in the study will begin in early 2013.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B brings in $6.4mm for Avaxia; adds $5mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice